Dossier 7 - Les surrogates endpoints

Références

Sommaire > Dossier 7 - Les surrogates endpoints > Références

Références

[1] Shyr Y, Shyr D. What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials? JAMA Oncol 2020 10.1001/jamaoncol.2020.1847

[2] Manyara AM, Davies P, Stewart D, et al. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ 2024;386:e078525 10.1136/bmj-2023-078525 [38981624]

[3] Manyara AM, Davies P, Stewart D, et al. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ 2024;386:e078524 10.1136/bmj-2023-078524 [38981645]

[4] Group, ICECaP Working, Sweeney C, Nakabayashi M, et al. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). JNCI Journal of the National Cancer Institute 2015;107:djv261 10.1093/jnci/djv261 [26409187]

[5] Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–14 10.1016/0002-9343(77)90874-9 [193398]

[6] Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15 10.1161/01.cir.79.1.8 [2642759]

[7] LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990;81:1721–33 10.1161/01.cir.81.5.1721 [2184951]

[8] Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203–12 10.1056/NEJMoa1300955 [25014686]

[9] Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–09 10.1056/NEJM199003223221203 [2407957]

[10] Barbarawi M, Kheiri B, Zayed Y, et al. Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis. JAMA Cardiol 2019;4:765–76 10.1001/jamacardio.2019.1870 [31215980]

[11] LeBoff MS, Chou SH, Ratliff KA, et al. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. N Engl J Med 2022;387:299–309 10.1056/NEJMoa2202106 [35939577]

[12] Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005;366:1849–61 10.1016/S0140-6736(05)67667-2 [16310551]

[13] Das Pradhan A, Glynn RJ, Fruchart J-C, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 2022;387:1923–34 10.1056/NEJMoa2210645 [36342113]

[14] Kristeleit R, Lisyanskaya A, Fedenko A, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. The Lancet Oncology 2022;23:465–78 10.1016/S1470-2045(22)00122-X [35298906]

[15] Weintraub WS, Lüscher TF, Pocock S. The perils of surrogate endpoints. Eur. Heart J. 2015;36:2212–18 10.1093/eurheartj/ehv164 [25975658]

[16] Hwang TJ, Carpenter D, Lauffenburger JC, et al. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern Med 2016;176:1826–33 10.1001/jamainternmed.2016.6008 [27723879]

[17] Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 2005;2013:CD002230 10.1002/14651858.CD002230.pub2 [15674893]

[18] Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 2006;5:173–86 10.1002/pst.207 [17080751]

[19] Buyse M, Molenberghs G, Paoletti X, et al. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials: Statistical evaluation of surrogate endpoints. Biometrical Journal 2016;58:104–32 10.1002/bimj.201400049

[20] Ciani O, Buyse M, Drummond M, et al. Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. Nature Reviews Drug Discovery 2016;15:516 10.1038/nrd.2016.81

[21] Bujkiewicz S, Thompson JR, Spata E, et al. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints. Stat Methods Med Res 2017;26:2287–318 10.1177/0962280215597260

[22] Ciani O, Davis S, Tappenden P, et al. VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. International Journal of Technology Assessment in Health Care 2014;30:312–24 10.1017/S0266462314000300

[23] IQWiG. Validity of surrogate endpoints in oncology. Cologne 2011.

[24] Norsworthy KJ, Gao X, Ko C-W, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. JCO 2022;40:847–54 10.1200/JCO.21.01548 [34890212]

[25] Lassere MN, Johnson KR, Schiff M, et al. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES). BMC Med Res Methodol 2012;12:27 10.1186/1471-2288-12-27 [22409774]

[26] Xie W, Regan MM, Buyse M, et al. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clinical Oncology 2017:JCO.2017.73.9987 10.1200/JCO.2017.73.9987

[27] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet 2014;384:164–72 10.1016/S0140-6736(13)62422-8 [24529560]

[28] Papanikos T, Thompson JR, Abrams KR, et al. A novel approach to bivariate meta-analysis of binary outcomes and its application in the context of surrogate endpoints 2020.

[29] Branchoux S, Sofeu CL, Gaudin A-F, et al. Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial. ESMO Open 2021;7:100340 10.1016/j.esmoop.2021.100340 [34929616]

[30] Baker SG. Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials. Stat Med 2018;37:507–18 10.1002/sim.7561 [29164641]

[31] Sofeu CL, Emura T, Rondeau V. One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints. Stat Med 2019;38:2928–42 10.1002/sim.8162 [30997685]

[32] Head ML, Holman L, Lanfear R, et al. The extent and consequences of p-hacking in science. PLoS Biology 2015;13:e1002106 10.1371/journal.pbio.1002106 [25768323]

[33] Data dredging - Wikipedia 2021. Available at: https://en.wikipedia.org/wiki/Data_dredging Accessed August 30, 2021.

[34] Kerr NL. HARKing: hypothesizing after the results are known. Pers Soc Psychol Rev 1998;2:196–217 10.1207/s15327957pspr0203_4 [15647155]

[35] Siontis KC, Hernandez-Boussard T, Ioannidis JPA. Overlapping meta-analyses on the same topic: survey of published studies. BMJ 2013;347:f4501 10.1136/bmj.f4501 [23873947]

[36] Ioannidis JPA. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. The Milbank Quarterly 2016;94:485–514 10.1111/1468-0009.12210 [27620683]

[37] Byrne P, Demasi M, Jones M, et al. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. JAMA Intern Med 2022;182:474–81 10.1001/jamainternmed.2022.0134 [35285850]

[38] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet 2005;366:1267–78 10.1016/S0140-6736(05)67394-1 [16214597]

[39] Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016;316:1289–97 10.1001/jama.2016.13985 [27673306]

[40] Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur. Heart J. 2018;39:1172–80 10.1093/eurheartj/ehx566 [29069377]

[41] Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990;82:1916–24 10.1161/01.cir.82.6.1916 [2242517]

[42] Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995;91:2274–82 10.1161/01.cir.91.8.2274 [7697857]

[43] Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. Br Heart J 1993;69:S42-7 10.1136/hrt.69.1_suppl.s42 [8427764]

[44] Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995;76:10C-17C 10.1016/s0002-9149(99)80465-2 [7572677]

[45] Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162–69 10.1161/hc1002.105136 [11889008]

[46] Gould AL, Davies GM, Alemao E, et al. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther 2007;29:778–94 10.1016/j.clinthera.2007.05.012 [17697899]

[47] Holme I. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. Controlled Clinical Trials 1996;17:13–22 10.1016/0197-2456(95)00083-6 [8721798]

[48] Johnson KR, Freemantle N, Anthony DM, et al. LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE). Journal of Clinical Epidemiology 2009;62:328–36 10.1016/j.jclinepi.2008.06.004 [18834708]

[49] Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946–52 10.1161/01.cir.97.10.946 [9529261]

[50] van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:589–624 10.1002/sim.1040 [11836738]

[51] Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559–73 10.1002/sim.1187 [12111920]

[52] HTA CG. Guidance on outcomes for joint clinical assessments.

[53] Morgenstern H. Uses of ecologic analysis in epidemiologic research. Am J Public Health 1982;72:1336–44 10.2105/ajph.72.12.1336 [7137430]

[54] Geissbühler M, Hincapié CA, Aghlmandi S, et al. Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study. BMC Med Res Methodol 2021;21:123 10.1186/s12874-021-01310-0 [34130658]

[55] Berlin JA, Santanna J, Schmid CH, et al. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002;21:371–87 10.1002/sim.1023 [11813224]

[56] Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 2009;373:1175–82 10.1016/S0140-6736(09)60447-5 [19329177]

[57] Naci H, Davis C. Inappropriate use of progression-free survival in cancer drug approvals. BMJ-BRITISH MEDICAL JOURNAL 2020;368:m770 10.1136/bmj.m770 [32156802]

[58] Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 2017;15:134 10.1186/s12916-017-0902-9 [28728605]

[59] Hilal T, Gonzalez-Velez M, Prasad V. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. JAMA Internal Medicine 2020;180:1108–15 10.1001/jamainternmed.2020.2250 [32539071]

[60] Chen EY, Joshi SK, Tran A, et al. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Internal Medicine 2019;179:642–47 10.1001/jamainternmed.2018.8351 [30933235]

[61] Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Internal Medicine 2019;179:906–13 10.1001/jamainternmed.2019.0462 [31135808]

[62] Downing NS, Aminawung JA, Shah ND, et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014;311:368–77 10.1001/jama.2013.282034 [24449315]

[63] Naci H, Smalley KR, Kesselheim AS. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. JAMA 2017;318:626–36 10.1001/jama.2017.9415 [28810023]

[64] Pease AM, Krumholz HM, Downing NS, et al. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ-BRITISH MEDICAL JOURNAL 2017;357:j1680 10.1136/bmj.j1680 [28468750]

[65] Prasad V, Kim C, Burotto M, et al. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Internal Medicine 2015;175:1389–98 10.1001/jamainternmed.2015.2829 [26098871]

[66] Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218–24 10.1200/JCO.2007.11.8836 [18024867]

[67] Ciani O, Buyse M, Garside R, et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol 2015;68:833–42 10.1016/j.jclinepi.2015.02.016 [25863582]

[68] Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Internal Medicine 2015;175:1992–94 10.1001/jamainternmed.2015.5868 [26502403]

[69] Chen EY, Haslam A, Prasad V. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. JAMA Internal Medicine 2020;180:912–14 10.1001/jamainternmed.2020.1097 [32338703]

[70] Chen EY, Raghunathan V, Prasad V. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Internal Medicine 2019;179:915–21 10.1001/jamainternmed.2019.0583 [31135822]

[71] Wallach JD, Ciani O, Pease AM, et al. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study. BMC Med 2018;16:45 10.1186/s12916-018-1023-9 [29562926]

[72] Ciani O, Manyara AM, Davies P, et al. A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials. EClinicalMedicine 2023;65:102283 10.1016/j.eclinm.2023.102283 [37877001]